On August 31, 2026 Alligator Bioscience AB ("Alligator Bioscience" or the "Company") reported it has prepared a prospectus (the "Prospectus") relating to the rights issue of units of approximately SEK 125.6 million, which was resolved by the board of directors on 23 July 2026, and approved by the extraordinary general meeting held on 26 August 2026 (the "Rights Issue"). The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Summary

Anyone who is registered as a shareholder in Alligator Bioscience on the record date, 2 September 2026, will receive five (5) unit rights for each existing ordinary share in the Company. One (1) unit right entitles the holder to subscribe for one (1) unit. Each unit consists of two (2) ordinary shares, one (1) warrant series TO 15 and one (1) warrant series TO 16. The warrants series TO 15 and TO 16 are intended to be admitted to trading on Nasdaq Stockholm.
The Rights Issue entails the issuance of a maximum of 3,140,534,240 units, corresponding to 6,281,068,480 ordinary shares, 3,140,534,240 warrants series TO 15 and 3,140,534,240 warrants series TO 16.
The subscription price in the Rights Issue has been set to SEK 0.04 per unit, corresponding to SEK 0.02 per ordinary share. The warrants series TO 15 and TO 16 are issued free of charge.
One (1) warrant series TO 15 entitles the holder to subscription of one (1) ordinary share in the Company during the period from and including 8 January 2027 up to and including 22 January 2027.
One (1) warrant series TO 16 entitles the holder to subscription of one (1) ordinary share in the Company during the period from and including 7 January 2028 up to and including 21 January 2028.
Upon full subscription in the Rights Issue, Alligator Bioscience will initially receive approximately SEK 125.6 million before issue costs. In the event the warrants series TO 15 and TO 16 are fully exercised for subscription of new ordinary shares, at the same subscription price per ordinary share as in the Rights Issue, the Company will receive additional proceeds of approximately SEK 62.8 million in January 2027 and approximately SEK 62.8 million in January 2028, before issue costs.
The subscription period in the Rights Issue will run from and including 4 September 2026 up to and including 18 September 2026.
The Company intends to use the net proceeds from the Rights Issue, after repayment of the bridge loans, to refocus its operations on maintaining the future royalty upside from HLX22, fund the wind-down of its mitazalimab development activities, thereby providing funding to at least the topline data readout from the ongoing HLX22 Phase 3 trial, as well as for general corporate purposes and near-term strategic opportunities within mitazalimab.
The Rights Issue is covered by subscription undertakings up to approximately 2 percent and by guarantee commitments up to approximately 45 percent, corresponding to a total of approximately 47 percent of the Rights Issue.
For complete information on the Rights Issue, please see the published Prospectus.

The Prospectus
The Prospectus has been prepared in connection with the forthcoming Rights Issue and has today, on 31 August 2026, been approved and registered by the Swedish Financial Supervisory Authority. The Prospectus, containing complete terms and conditions, is available on the Company’s website (www.alligatorbioscience.com) and APREA Partners’ website (www.apreapartners.com). The Prospectus will also be available on the Swedish Financial Supervisory Authority’s website (www.fi.se). Subscription forms will be available on the Company’s and APREA Partners’ respective websites.

Time plan for the Rights Issue

Last day of trading in shares including right to receive unit rights 31 August 2026
First day of trading in shares excluding right to receive unit rights 1 September 2026
Record date for the right to receive unit rights 2 September 2026
Trading in unit rights 4 – 15 September 2026
Subscription period 4 – 18 September 2026
Announcement of the outcome of the Rights Issue Around 22 September 2026
Trading in paid subscribed units (BTU) 4 September – 6 October 2026
Advisers
APREA Partners AB acts as financial adviser in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal adviser to Alligator Bioscience. Vator Securities AB acts as the issuing agent in connection with the Rights Issue.

(Press release, Alligator Bioscience, AUG 31, 2026, View Source [SID1234670439])